Stem Cell Clinic

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering

By Global News Feed

FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the pricing of a public offering of an aggregate of 1,665,219 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 1,665,219 shares of common stock at a combined public offering price of $2.875 per share (or per common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $2.75 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about May 1, 2024, subject to the satisfaction of customary closing conditions.

Follow this link:
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering

Mustang Bio Announces Pricing of $4 Million Public Offering

By Global News Feed

WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the pricing of a public offering of an aggregate of 16,877,638 shares of its common stock (or common stock equivalents in lieu thereof), Series A-1 warrants to purchase up to 16,877,638 shares of common stock, Series A-2 warrants to purchase up to 16,877,638 shares of common stock and Series A-3 warrants to purchase up to 16,877,638 shares of common stock, at a combined public offering price of $0.237 per share (or per common stock equivalent in lieu thereof) and accompanying warrants. The warrants will have an exercise price of $0.237 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The Series A-1 warrants will expire five years from the date of stockholder approval, the Series A-2 warrants will expire twenty-four months from the date of stockholder approval and the Series A-3 warrants will expire nine months from the date of stockholder approval. The closing of the offering is expected to occur on or about May 2, 2024, subject to the satisfaction of customary closing conditions.

Go here to read the rest:
Mustang Bio Announces Pricing of $4 Million Public Offering

Combined General Meeting of May 22, 2024 – Availability of preparatory documents

By Global News Feed

Paris – April 30, 2024 – EUROAPI’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 22, 2024 at 10:00 a.m. (CET) at the Centre de Conférences Verso, 52 rue de la Victoire 75009 Paris.The notice of meeting was published at the French official legal announcement publication (BALO) on Friday April 12, 2024 (bulletin n°45) and the convening notice (avis de convocation) was published in the Actu-juridique.fr, a French journal of legal notice, on April 29, 2024.

Read the original:
Combined General Meeting of May 22, 2024 - Availability of preparatory documents

UM, CUHK jointly hold symposium on stem cells and regenerative medicine – gcs.gov.mo

By Stem Cell Medicine

The Faculty of Health Sciences (FHS) of the University of Macau (UM) and the School of Medicine of the Chinese University of Hong Kong (CUHK) jointly held the 10th CUHK International Symposium on Stem Cell Biology and Regenerative Medicine and the 3rd Guangdong-Hong Kong-Macau Greater Bay Area International Conference on Regenerative Medicine. The two-day event attracted more than 100 renowned scholars, clinical medical experts, industry professionals, researchers and students from overseas, mainland China, Hong Kong, and Macao. They engaged in in-depth discussions on the advancements in the field of stem cells and regenerative medicine, as well as their clinical translation.

In his speech, Ge Wei, vice rector of UM, said that the Guangdong-Hong Kong-Macao Greater Bay Area is an important region for the development of medical science and technology in China. To support the countrys implementation of the Greater Bay Area development strategy, UM is committed to biomedical research and the training of outstanding talent in regenerative medicine, providing impetus to the sustainable development of the biomedical industry in the Greater Bay Area. The conference not only deepened the academic exchanges and cooperation between UM and CUHK, but also provided a valuable opportunity for students from both universities to exchange ideas.

Rocky Tuan, vice-chancellor and president of CUHK, said in his speech that regenerative medicine is a major breakthrough in biomedicine in the 21st century. Significant advances in stem cell biology and the development of smart biomaterial engineering have provided a solid foundation for future tissue regeneration to treat injuries and diseases. The conference provided a platform for the exchange of innovative research ideas and an opportunity to inspire students and young scientists to learn and collaborate.

The symposium featured eight keynote lectures and 39 sub-forum presentations, delivered by domestic and foreign experts in stem cell biology, regenerative medicine, bioengineering and other cutting-edge fields, which marked the highest number of presentations in the history of the event. During the keynote lecture session, Tuan presented the latest developments in stem cell technology and social problems that need to be solved; Qin Ling, fellow of the American Institute for Medical and Biological Engineering and renowned professor of orthopaedics and traumatology, shared the research progress of biodegradable metal-derived magnesium in bone regeneration and its clinical translation; Chang Jiang, fellow of the UK Royal Society of Chemistry and professor at the Chinese Academy of Sciences, talked about the prospects for the application of bioactive ceramics and composite materials in different tissue regeneration and disease treatment. In addition, a student forum was held during the symposium for the first time, providing students from both universities with a platform for academic exchanges and presentation of their research results.

Xu Renhe, associate dean of UMs FHS, and Li Gang, professor in CUHKs School of Medicine, served as co-chairs of the organising committee of the symposium. Co-organisers of the symposium included the Prince of Wales Hospital and the Center for Research Excellence of CUHK. Chuxia Deng, dean of UMs FHS also attended the event.

More here:
UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo

→←